In a showdown with AstraZeneca, Pfizer posts solid — and very familiar — PhIII breast cancer data for talazoparib
Pfizer $PFE came through with positive numbers for its Phase III study of its PARP inhibitor talazoparib in advanced breast cancer — lining up right alongside AstraZeneca’s $AZN leading rival Lynparza. And the results position Pfizer to join the PARP lineup as the fourth player to toe up to the market threshold — though maybe not in the lead position it was promised when the pharma giant bought the drug last year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.